Sanofi (SNY,SAN.PA) reported that the LEAP2MONO phase 3 study demonstrated that venglustat met the primary and three out of four key secondary endpoints in adults and pediatric patients with neurological manifestations of type 3 Gaucher disease. Venglustat demonstrated superiority versus enzyme replacement therapy in addressing neurological symptoms. Also, Venglustat was well tolerated overall with no new safety signals. Sanofi said it will pursue global regulatory filings for venglustat in GD3.
Houman Ashrafian, Executive Vice President and Head of Research and Development at Sanofi, said: "What excites us most is the potential to address critical unmet medical needs. A daily pill could make a serious difference for Gaucher patients facing neurological challenges."
Sanofi shares are trading at 79.20 euros, up 2.75%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.